111 related articles for article (PubMed ID: 26391571)
1. Invasive low-grade papillary urothelial carcinoma: an immunohistochemical study of 26 cases.
Tian W; Epstein JI
Hum Pathol; 2015 Dec; 46(12):1836-41. PubMed ID: 26391571
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic characteristics of 23 cases of invasive low-grade papillary urothelial carcinoma.
Watts KE; Montironi R; Mazzucchelli R; van der Kwast T; Osunkoya AO; Stephenson AJ; Hansel DE
Urology; 2012 Aug; 80(2):361-6. PubMed ID: 22857755
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/Internattional Society of Urologic Pathology.
Alsheikh A; Mohamedali Z; Jones E; Masterson J; Gilks CB
Mod Pathol; 2001 Apr; 14(4):267-72. PubMed ID: 11301341
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of MUC1 and P53 expressions in noninvasive papillary urothelial neoplasms of bladder, their relationship with tumor grade and role in the differential diagnosis.
Kaymaz E; Ozer E; Unverdi H; Hucumenoglu S
Indian J Pathol Microbiol; 2017; 60(4):510-514. PubMed ID: 29323063
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma.
Jung M; Kim B; Moon KC
Histopathology; 2019 Feb; 74(3):483-493. PubMed ID: 30286252
[TBL] [Abstract][Full Text] [Related]
6. Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study.
Samaratunga H; Khoo K
Histopathology; 2004 Jul; 45(1):55-64. PubMed ID: 15228444
[TBL] [Abstract][Full Text] [Related]
7. Histopathological and immunohistochemical study of papillary urothelial neoplasms of low malignant potential and grade associated with extensive invasive low-grade urothelial carcinoma.
Mai KT; Elmontaser G; Perkins DG; Yazdi HM; Stinson WA; Thijssen A
BJU Int; 2004 Sep; 94(4):544-7. PubMed ID: 15329109
[TBL] [Abstract][Full Text] [Related]
8. Invasive micropapillary urothelial carcinoma of the bladder.
Lopez-Beltran A; Montironi R; Blanca A; Cheng L
Hum Pathol; 2010 Aug; 41(8):1159-64. PubMed ID: 20381120
[TBL] [Abstract][Full Text] [Related]
9. Reduced immunohistochemical PTEN staining is associated with higher progression rate and recurrence episodes in non-invasive low-grade papillary urothelial carcinoma of the bladder.
Kulac I; Arslankoz S; Netto GJ; Ertoy Baydar D
Virchows Arch; 2018 Jun; 472(6):969-974. PubMed ID: 29368083
[TBL] [Abstract][Full Text] [Related]
10. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.
Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW
Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769
[TBL] [Abstract][Full Text] [Related]
11. Noninvasive micropapillary urothelial carcinoma: a clinicopathologic study of 18 cases.
Amin A; Epstein JI
Hum Pathol; 2012 Dec; 43(12):2124-8. PubMed ID: 22939957
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical expression of p63, p53 in urinary bladder carcinoma.
Koyuncuer A
Indian J Pathol Microbiol; 2013; 56(1):10-5. PubMed ID: 23924551
[TBL] [Abstract][Full Text] [Related]
13. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
[TBL] [Abstract][Full Text] [Related]
14. Expression of MUC1 (Ma695) in noninvasive papillary urothelial neoplasm according to the 2004 World Health Organization classification of the noninvasive urothelial neoplasm. An immunologic tool for the pathologist?
Garbar C; Mascaux C
Anal Quant Cytol Histol; 2011 Oct; 33(5):277-82. PubMed ID: 22611755
[TBL] [Abstract][Full Text] [Related]
15. Histologic grading of noninvasive papillary urothelial tumors: validation of the 1998 WHO/ISUP system by immunophenotyping and follow-up.
Yin H; Leong AS
Am J Clin Pathol; 2004 May; 121(5):679-87. PubMed ID: 15151208
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive squamous lesions in the urinary bladder: a clinicopathologic analysis of 29 cases.
Guo CC; Fine SW; Epstein JI
Am J Surg Pathol; 2006 Jul; 30(7):883-91. PubMed ID: 16819332
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
[TBL] [Abstract][Full Text] [Related]
18. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy.
Holmäng S; Andius P; Hedelin H; Wester K; Busch C; Johansson SL
J Urol; 2001 Apr; 165(4):1124-8; discussion 1128-30. PubMed ID: 11257652
[TBL] [Abstract][Full Text] [Related]
19. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder.
Quintero A; Alvarez-Kindelan J; Luque RJ; Gonzalez-Campora R; Requena MJ; Montironi R; Lopez-Beltran A
J Clin Pathol; 2006 Jan; 59(1):83-8. PubMed ID: 16394286
[TBL] [Abstract][Full Text] [Related]
20. Mixed low- and high-grade papillary urothelial carcinoma: histopathogenetic and clinical significance.
Mai KT; Flood TA; Williams P; Kos Z; Belanger EC
Virchows Arch; 2013 Oct; 463(4):575-81. PubMed ID: 23913166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
